GSK opts to co-develop experimental rheumatoid arthritis drug

GlaxoSmithKline has triggered an option under a 1996 joint partnership deal with Human Genome Sciences to co-develop LymphoStat-B, an experimental drug for rheumatoid arthritis. The two companies will split the costs of Phase III and Phase IV trials and share in the revenues from any successful product launch.

- read this report from the Washington Business Journal for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.